



## Commercial/Healthcare Exchange PA Criteria

*Effective: July 28, 2023*

**Prior Authorization:** Vowst (fecal microbiota spores, live-brpk)

**Products Affected:** Vowst (fecal microbiota spores, live-brpk) oral capsules

**Medication Description:** Indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in patients  $\geq 18$  years of age following antibacterial treatment for recurrent CDI.

**Covered Uses:** prevent recurrence of Clostridioides difficile infection (CDI)

**Exclusion Criteria:** Not indicated for treatment of CDI.

**Required Medical Information:**

1. Medical history

**Prescriber Restriction:** Must be prescribed by, or in consultation with, internal medicine, gastroenterologist, or infectious disease specialist

**Age Restriction:** 18 years and older

**Coverage Duration:** 1 treatment course (12 capsules/lifetime)

**Other Criteria:**

**Initial Approval Criteria**

1. **Prevention of recurrence of C. difficile infection (CDI)**
  - A. Age  $\geq 18$  years; **AND**
  - B. Diagnosis of at least 1 recurrent episode of CDI ( $\geq 2$  total CDI episodes); **AND**
  - C. Current episode of CDI must be controlled ( $< 3$  unformed/loose stools/day for 2 consecutive days); **AND**
  - D. Positive stool test for C. difficile within 30 days before prior authorization request; **AND**
  - E. Administration will occur 2 to 4 days following completion of antibiotic course for CDI treatment; **AND**
  - F. Bowel cleanse using magnesium citrate or polyethylene glycol electrolyte solution will occur on the day before the first dose of Vowst

**References:**

1. Product Information: VOWST™ oral capsules, fecal microbiota spores, live-brpk oral capsules. Aimmune Therapeutics Inc (per manufacturer), Brisbane, CA, 2023.





**Policy Revision history**

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	07/28/2023

